2026.09.14

Presentation Report: Aesthetic & Anti-aging Medicine World Congress (AMWC Japan 2026)

AMWC Japan 2026 Presentation Report

2026.09.09

Goda Lab, with Tokyo Relife Clinic as a Participating Member, Selected as One of 10 XPRIZE Healthspan Milestone 2 Awardees

Goda Lab, with Tokyo Relife Clinic, Selected as One of 10 XPRIZE Healthspan Finalist

2026.08.19

Tokyo Relife Clinic CEO Yoshiaki Furuyama to Speak at AMWC Japan 2026

Tokyo Relife Clinic CEO to Speak at AMWC Japan 2026

2026.04.02

Dr. Kensei Tsuzaka, M.D., Ph.D. Appointed as Chief Advisor at TOKYO RELIFE CLINIC

Dr. Kensei Tsuzaka Appointed as Chief Advisor at TOKYO RELIFE CLINIC

2026.03.04

Maki Nakao, M.D., Ph.D. Appointed as Clinic Director of TOKYO RELIFE CLINIC

Dr. Maki Nakao Appointed as Clinic Director of TOKYO RELIFE CLINIC

2025.11.06

Dr. Hidekazu Yamada Appointed as Chief Advisor of TOKYO RELIFE CLINIC

Dr. Hidekazu Yamada Appointed as Chief Advisor of TOKYO RELIFE CLINIC

2025.10.07

Recruitment Notice for Clinical Study Participants

Recruitment Notice for Clinical Study Participants

2025.10.01

TOKYO RELIFE CLINIC and the Goda Laboratory at the University of Tokyo Launch Joint Research

TOKYO RELIFE CLINIC and the Goda Laboratory Launch Joint Research

2025.10.01

TOKYO RELIFE CLINIC Launches Clinical Study on Aging Control

Clinical Study on Aging Control

2025.01.20

Why regenerative medicine is needed now?

As we enter the era of 100-year life expectancy, many people are seeking to lead healthy and affluent lives. At the same time, the aging of the population and the increase in lifestyle-related diseases are causing a fundamental reevaluation of the nature of medical care. It is inevitable that regenerative medicine will attract attention in order to meet these challenges.

2024.10.11

TOKYO RELIFE CLINIC's Clinical Research Initiatives

TRC initiated Japan's first clinical research to evaluate the efficacy and safety of stem cell-derived supernatants and exosomes in December 2024 after convening an Ethics Review Committee. This study, involving 60 patients, will begin in January 2025, with results expected by June 2025. Key Research Themes Efficacy and Safety Evaluation of Supernatants for Skin Rejuvenation Validation of Stem Cell-Derived Supernatants and Exosomes for Patients with Non-Specific Complaints Chief Director: Dr. Masashi Ishikawa Dr. Masashi Ishikawa is a leader in Japanese medicine, renowned for his achievements in regenerative medicine and liver transplantation. He is internationally recognized for his contributions and expertise.